EUCTR2007-006648-23-IT进行中（未招募）不适用
An exploratory, randomized, double-blind, placebo controlled study to assess the efficacy of multiple doses of omalizumab (Xolair) in cystic fibrosis complicated by allergic bronchopulmonary aspergillosis - ND
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •-Males/females age≥12 years -Cystic Fibrosis diagnosed by either gene profiling and/or sweat test -ABPA previously diagnosed according to the Cystic Fibrosis Foundation Consensus Conference recommendations ? minimal diagnostic criteria for diagnosis of ABPA in cystic fibrosis defined as:i)Acute or sub-acute clinical deterioration(cough,wheeze,exercise intolerance,exercise-induced asthma,change in pulmonary function,or increased sputum production)not attributable to another etiology. ii)Total serum IgE concentration of >500IU/mL(1200 ng/mL).iii)Immediate cutaneous reactivity to Aspergillus(prick skin test wheal>3mm in diameter with surrounding erythema,while the patient is not being treated with systemic antihistamines)or in vitro demonstration of IgE antibody to A.fumigatus.iv)One of the following: a)precipitans to A.fumigatus or in vitro demonstration of IgG antibody to A.fumigatus or b)new or recent abnormalities on chest radiography(infiltrates or mucus plugging)or chest CT(bronchiectasis)that has not cleared with antibiotics and standard physiotherapy.-Total serum IgE level of>500IU/ml(will be measured locally at Screening Visit).Screening IgE levels will determine the dose throughout the study.-Patients who are being treated for ABPA by any oral corticosteroid(for at least 8 weeks prior to the first dose of study treatment ?with an OCS entry dose of minimum 5mg/maximum 40mg per day in prednisolone equivalence).Patients must have a history of at least one unsuccessful attempt to taper steroids defined as in the clinician?s judgment,an ABPA exacerbation during taper(chronic ABPA group)or Patients who present with an acute episode of ABPA,either as a first presentation or as a recurrence,and who were taking a maximum dose of prednisolone of 20mg/day(or equivalent)prior to the ABPA flare(acute ABPA group)-Patients must have an FEV1,as measured at the Baseline Visit, of no lower than 90% of their previous best FEV1 as measured at Screening Visit.-FEV1>40% of predicted in patients aged<16years old,and FEV1 of >30% of predicted is acceptable in patients aged ≥16 years old as measured after 12 hour washout of LABA\6 hours of SABA. -Female subjects of childbearing potential must be advised that systemic corticosteroids pose a known risk to mother and fetus. Xolair is FDA pregnancy category B. This medication is not expected to be harmful to an unborn.However,patients are advised to use adequate methods of contraception,from the time of screening and for the duration of the study,through study completion. Periodic abstinence(e.g., calendar, ovulation, symptothermal, post-ovulation methods)and withdrawal are not adequate methods of contraception. -Female subjects who report surgical sterilization must have had the procedure at least six (6)months prior to initial dosing.Surgical sterilization procedures should be supported with clinical documentation made available to the sponsor and noted in the Relevant Medical History/Current Medical Conditions section of the CRF.-Postmenopausal females must have had no regular menstrual bleeding for at least one(1)year prior to initial dosing.Menopause will be confirmed by a plasma FSH level of>40IU/L at screening. -Prior to administration of any study procedures,eligible patients(and parents for patients below age 16)must provide written informed consent. -Subjects must be able to communicate well with the investigator;understand and comply with the requirements of th
排除标准
- •-History of cancer in the past 10 years (except surgically-cured basal cell or squamous cell skin cancer). -Any previous history of anaphylaxis. -Any other medical condition that in the opinion of the investigator may cause the patient to be unsuitable for completion of the study or place the patient at potential risk from being in the study. -Pregnant and lactating women. -Prior Xolair exposure. -Lung or other transplant. -Participation in any clinical trial within four (4) weeks prior to initial dosing or longer if required by local regulations, and for any other limitation of participation based on local regulations. -Hemoglobin levels below 10.0 g/dl at screening. -History of immunodeficiency diseases. -Significant illness other than CF/ABPA within two (2) weeks prior to initial dosing. -A past medical history of clinically significant ECG abnormalities.12. Patients who are known to be positive for chronic atypical Mycobacteria and Burkholderia cepacia including subspecies.
研究者
相似试验
进行中（未招募）
1 期
An exploratory, randomized, double-blind, placebo controlled study to assess the efficacy of multiple doses of omalizumab in cystic fibrosis complicated with allergic bronchopulmonary aspergillosisEUCTR2007-006648-23-IEovartis Pharma Services AG60
已完成
4 期
An exploratory, randomized, double-blind, placebo controlled study to assess the efficacy of multiple doses of omalizumab in cystic fibrosis complicated with allergic bronchopulmonary aspergillosismucoviscidosis/cystic fibrose10010613NL-OMON33750Harrison Clinical Research Benelux30
进行中（未招募）
不适用
An exploratory, randomized, double-blind, placebo controlled study to assess the efficacy of multiple doses of omalizumab in cystic fibrosis complicated with allergic bronchopulmonary aspergillosisEUCTR2007-006648-23-DEovartis Pharma Services AG60
已完成
不适用
An Inhaled Allergen Challenge (IAC) study to evaluate the effects of SMP-028 in subjects with mild to moderate asthmaAsthmaRespiratoryISRCTN29389604Dainippon Sumitomo Pharma Europe Ltd (UK)24
进行中（未招募）
不适用
An exploratory, randomised, double-blind, placebo controlled crossover study to assess the efficacy of 20 mg Rupatadine on the treatment of mastocytosis symptoms - Study on Mastocytosis for Rupatadine TreatmentMastocytosis is characterized by an excessive increase in the number of mast cells in different tissues. Symptoms result either from organ infiltration or frequently from the release of proinflammatory mast cell mediators. Whereas in cutaneous mastocytosis the increase in mast cell numbers is limited to the skin, systemic mastocytosis is characterized by multifocal lesions in the bone marrow and/or in various extracutaneous organs.MedDRA version: 12.1Level: LLTClassification code 10052577Term: Pure dermal mastocytosisMedDRA version: 12.1Level: LLTClassification code 10056452Term: Indolent systemic mastocytosisEUCTR2010-021001-21-DEAllergie-Centrum-Charité